Timothy Liesching, MD
Pulmonary Disease · Burlington, MANPI 1730136433
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,523 of the $5,523 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Boehringer Ingelheim.
Across 6 payments — averaging $920.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
Across 20 payments — averaging $7050.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$106K
- Eli Lilly$35K
What the payments were for
- Speaking & faculty fees$5,523100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $5,523 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$5,523
How this compares
$5,523 in reported general payments places this provider in the 80th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $24,235 |
| Advair DiskusFluticasone Propion/Salmeterol | 19 | $8,883 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,926 |
| Ipratropium Bromide | 15 | $1,082 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $974 |
| Ventolin HfaAlbuterol Sulfate | 12 | $828 |
| Prednisone | 22 | $65 |
| Azithromycin | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Burlington
- Adam SmithBurlington$296K
- Carla LambBurlington$27K
- Cyrus KholdaniBurlington$16K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.